ASCO18: Celgene makes its case as CAR-T rival in lymphoma – BioPharma Dive
|
ASCO18: Celgene makes its case as CAR–T rival in lymphoma
BioPharma Dive Celgene's experimental cell therapy JCAR017, or liso-cel, could prove competitive in lymphoma with already on-market treatments from Gilead and Novartis, suggest updated clinical results presented Sunday at the annual meeting of the American Society of … |
